Delcath Systems Inc.’s (NSDQ:DCTH) ChemoSat organ-targeting chemotherapy system will get a pre-new drug application meeting with the FDA mid-January 2012, the company announced this week.
The ChemoSat device uses a system of tubes to localize the delivery of toxic chemotherapy agents by isolating the targeted organ — in this case, the liver — from the rest of the body’s bloodstream.
Delcath Systems Inc.’s (NSDQ:DCTH) Chemosat organ-targeting chemotherapy system extended the lives of terminal eye cancer patients by several months without disease progression, researchers said.
Melanoma of the eye often spreads to the liver, generally killing a patient in 1 to 2 months, according to a press release. Patients who received targeted treatment to saturate the liver lived an average of 8.1 months, compared to 1.6 months for patients receiving the best alternative care.
Contact: Emma Mason
[email protected]
ECCO-the European CanCer Organisation
Stockholm, Sweden: Melanoma of the eye (ocular or uveal melanoma) frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients live for a year. Now, final results from a phase III study have demonstrated that a new treatment significantly extends the time patients can live without the disease progressing.
Delcath Systems Inc. (NSDQ:DCTH) saw share prices drop 11 percent on news that its flagship cancer therapy device presented inconclusive results in treatment of colorectal cancer.
Sixteen patients with very late stage colorectal cancer participated in Delcath’s phase II study of its Chemosat focused chemotherapy delivery system, which uses a series of tubes to aim chemotherapy drugs at a specific organ and then filter the blood to remove the toxins before returning it to the body.
Delcath Systems Inc. (NSDQ:DCTH) CEO Eamonn Hobbs is in a good mood these days.
After raking in $33.8 million, Delcath Systems Inc. (NSDQ:DCTH) closed its public offering of 5.2 million shares.
According to a Securities & Exchange Commission filing, the New York-based company plans to use the proceeds from the sale to fund "clinical trials, research & development, obtaining regulatory approvals, manufacturing, operations, sales, commercialization of its products and other general corporate purposes including capital expenditures and working capital."
